期刊
LEUKEMIA
卷 32, 期 2, 页码 263-272出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2017.210
关键词
-
资金
- National Health and Medical Research Council of Australia
- Australian Research Council
- Cancer Institute NSW
- Cure Cancer Australia Foundation
- Anthony Rothe Memorial Trust
- Ian Potter Foundation
- UNSW Australia
- Translational Cancer Research Network of the Cancer Institute of NSW
- Wilhelm-Sander-Stiftung
- Cancer Council SA Beat Cancer Project
- Medvet Laboratories Pty Ltd
- Government of South Australia
- Medical Research Council [MC_PC_12009] Funding Source: researchfish
Prognostic gene expression signatures have been proposed as clinical tools to clarify therapeutic options in acute myeloid leukemia (AML). However, these signatures rely on measuring large numbers of genes and often perform poorly when applied to independent cohorts or those with older patients. Long intergenic non-coding RNAs (lincRNAs) are emerging as important regulators of cell identity and oncogenesis, but knowledge of their utility as prognostic markers in AML is limited. Here we analyze transcriptomic data from multiple cohorts of clinically annotated AML patients and report that (i) microarrays designed for coding gene expression can be repurposed to yield robust lincRNA expression data, (ii) some lincRNA genes are located in close proximity to hematopoietic coding genes and show strong expression correlations in AML, (iii) lincRNA gene expression patterns distinguish cytogenetic and molecular subtypes of AML, (iv) lincRNA signatures composed of three or four genes are independent predictors of clinical outcome and further dichotomize survival in European Leukemia Net (ELN) risk groups and (v) an analytical tool based on logistic regression analysis of quantitative PCR measurement of four lincRNA genes (LINC4) can be used to determine risk in AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据